http://onthepharm.net/2007/04/how-sepracor-could-make-a-buttload-of-money.html Life on the pharm Sat, 13 Mar 2010 17:06:35 -0800 http://wordpress.org/?v=2.8.6 hourly 1 http://onthepharm.net/2007/04/how-sepracor-could-make-a-buttload-of-money.html/comment-page-1#comment-177068 What the GSK man asked, and what he fears :: OnThePharm Wed, 12 Sep 2007 03:21:46 +0000 http://onthepharm.net/2007/04/how-sepracor-could-make-a-buttload-of-money.html#comment-177068 [...] That’ll work better than your fancy brochures and your formulary negotiations. [...] [...] That'll work better than your fancy brochures and your formulary negotiations. [...]

]]> http://onthepharm.net/2007/04/how-sepracor-could-make-a-buttload-of-money.html/comment-page-1#comment-74467 Jonathan Wed, 16 May 2007 21:44:07 +0000 http://onthepharm.net/2007/04/how-sepracor-could-make-a-buttload-of-money.html#comment-74467 I 100% agree with you on your post. In school we were taught that although Xopenex produced a statistically significant reduction in HR, the reduction was not clinically significant (something like 3-5 BPM) and as a result of its cost, it is generally avoided. If however, the drug companies did lower its price, they would be able to get a portion of the market from Albuterol. I 100% agree with you on your post. In school we were taught that although Xopenex produced a statistically significant reduction in HR, the reduction was not clinically significant (something like 3-5 BPM) and as a result of its cost, it is generally avoided. If however, the drug companies did lower its price, they would be able to get a portion of the market from Albuterol.

]]>